The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 13, 2015

Filed:

Sep. 20, 2013
Applicant:

Queensland University of Technology, Queensland, AU;

Inventors:

Zee Upton, Queensland, AU;

Jennifer Ann Kricker, Queensland, AU;

Assignee:

Queensland University of Technology, Brisbane, Queensland, AU;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/30 (2006.01); A61K 38/39 (2006.01); A61P 35/00 (2006.01); C07K 14/65 (2006.01); A61K 47/48 (2006.01); A61K 38/17 (2006.01); C07K 14/71 (2006.01); C07K 14/78 (2006.01);
U.S. Cl.
CPC ...
A61K 47/48246 (2013.01); A61K 38/1709 (2013.01); A61K 38/30 (2013.01); A61K 38/39 (2013.01); C07K 14/71 (2013.01); C07K 14/78 (2013.01);
Abstract

A method is provided for treating a disease or condition characterized by aberrant epithelial cell proliferation and/or migration. One step of the method can include administering to a mammal an agent which disrupts an isolated protein complex including: insulin-like growth factor I (IGF-I); an insulin-like growth factor binding protein (IGFBP) selected from IGFBP-3 and IGFBP-5; and vitronectin; or which prevents formation of the isolated protein complex, to thereby treat the disease or condition in the mammal. The agent is selected from the group consisting a polypeptide that is distinguished from IGF-II by substitution of at least one amino acid residue, wherein the polypeptide disrupts the isolated protein complex.


Find Patent Forward Citations

Loading…